Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 10.51% on an annualized basis…
Canaccord Genuity Initiates Coverage On Vertex Pharmaceuticals with Hold Rating, Announces Price Target of $311
Canaccord Genuity analyst Whitney Ijem initiates coverage on Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold rating and announces Price Target of $311.
Benzinga’s Top Ratings Upgrades, Downgrades For January 17, 2023
Upgrades For Casa Systems Inc (NASDAQ:CASA), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform.…
Jefferies Downgrades Vertex Pharmaceuticals to Hold, Announces $340 Price Target
Jefferies analyst Michael Yee downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Buy to Hold and announces $340 price target.
Entrada Therapeutics Stock Gains On Licensing Pact With Vertex For Form Of Neuromuscular Disorder
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Entrada Therapeutics Inc (NASDAQ:TRDA) announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV)…
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $7,900 Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 12.09% on an annualized basis…
6 Analysts Have This to Say About Vertex Pharmaceuticals
Vertex Pharmaceuticals (NASDAQ:VRTX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Argus Research Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $340
Argus Research analyst Jasper Hellweg maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $320 to $340.
Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 11.12% on an annualized basis producing an average annual return of 17.93%. Currently, Vertex Pharmaceuticals has a market capitalization of $78.36 billion.